MedTrace Logo

Effect of Lithium Therapy on Long COVID Symptoms

NCT05618587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-03-05

Study results available
· View outcomes & findings →

Summary

This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.

Conditions

Interventions

DRUG

Lithium

Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.

DRUG

Placebo

Inactive pill

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Thomas Guttuso, Jr., MD · University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-28
Primary Completion
2023-07-21
Completion
2023-07-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618587 on ClinicalTrials.gov